Presentation

BONESUPPORT is an emerging leader in orthobiologics that targets the major orthopaedic markets in the US and Europe. It develops and commercialises injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs directly into the bone void. BONESUPPORT’s marketed synthetic bone graft substitutes are CERAMENT BONE VOID FILLER, CERAMENT G and CERAMENT V, all based on the novel and proprietary CERAMENT technology platform.

Recent highlights
Net sales in Q2 amounted to SEK 74.6M (51.8) and increased by 44% (32% at constant exchange rates), with the North America segment reporting a 58% sales increase (40% at constant exchange rates).
In January, BONESUPPORT signed a distribution agreement with OrthoPediatrics Corp. to distribute CERAMENT® BONE VOID FILLER to pediatric hospitals within the US. In May, BONESUPPORT announced that its antibiotic eluting product CERAMENT G has received market authorisation from FDA through a De Novo process for the indication of osteomyelitis. CERAMENT G is the first and only bone graft, with antibiotic elution, approved for the US market. Lastly, the company announced in June that its products CERAMENT G and CERAMENT V have achieved private coverage in South Africa.

Outlook
Following the recent FDA approval, the company will focus on the launch of CERAMENT G in the US in Q3. A study of health economic analysis of the one-step procedure with CERAMENT G is also expected to be completed in Q2. The company’s annual sales growth target is 40%.